Dilated cardiomyopathy

Hemostemix Announces the First of a Series of 2021 Video Interviews with ACP-01 Recipients: What the Successful Compassionate Treatment of Ischemic Cardiomyopathy Looks Like After 13 Years

Tuesday, September 14, 2021 - 2:10pm

Hemostemix is a publicly traded autologous stem cell therapy company, founded in 2003.

Key Points: 
  • Hemostemix is a publicly traded autologous stem cell therapy company, founded in 2003.
  • A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia.
  • Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation.
  • This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable.

$304.5 Million Worldwide Dilated Cardiomyopathy Therapeutics Industry to 2027 - Impact of COVID-19 on the Market - ResearchAndMarkets.com

Wednesday, December 16, 2020 - 4:01pm

The "Dilated Cardiomyopathy Therapeutics - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Dilated Cardiomyopathy Therapeutics - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • The 137-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021.
  • The U.S. Market is Estimated at $89.7 Million, While China is Forecast to Grow at 4.2% CAGR
    The Dilated Cardiomyopathy Therapeutics market in the U.S. is estimated at US$89.7 Million in the year 2020.
  • Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$45.8 Million by the year 2027.

Global Dilated Cardiomyopathy Epidemiology Forecast to 2030 - ResearchAndMarkets.com

Thursday, October 8, 2020 - 2:35pm

The "Dilated Cardiomyopathy (DCM) - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Dilated Cardiomyopathy (DCM) - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
  • This report delivers an in-depth understanding of the disease, historical and forecasted Dilated Cardiomyopathy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • What are the various recent and upcoming events which are expected to improve the diagnosis of Dilated Cardiomyopathy?
  • Quantify patient populations in the global Dilated Cardiomyopathy market to improve product design, pricing, and launch plans
    The Dilated Cardiomyopathy Epidemiology Model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies.

MyoKardia Doses First Patient in Phase 2 Clinical Trial of Danicamtiv in Genetic Dilated Cardiomyopathy

Wednesday, September 9, 2020 - 1:00pm

Danicamtiv is MyoKardias most advanced clinical candidate being developed for the treatment of genetic dilated cardiomyopathy (DCM) and other targeted populations with conditions of reduced systolic function.

Key Points: 
  • Danicamtiv is MyoKardias most advanced clinical candidate being developed for the treatment of genetic dilated cardiomyopathy (DCM) and other targeted populations with conditions of reduced systolic function.
  • MyoKardias Phase 2 study of danicamtiv will enroll patients with DCM with documented genetic variants of MYH7 or titin.
  • MyoKardia intends to advance danicamtiv in further clinical studies to characterize clinical benefit, starting with a Phase 2 clinical trial in patients with genetic dilated cardiomyopathy.
  • Voors, et al, European Journal of Heart Failure, 2020
    Sinagra, et al, (editors), Dilated Cardiomyopathy: From Genetics to Clinical Management, Springer 2019
    Lund et al.

Dilated Cardiomyopathy (DCM) Market Insights and Outlook 2017-2030 - Epidemiology, Pipeline, Approved & Emerging Drugs, Competitive Intelligence

Friday, August 21, 2020 - 7:45pm

The Dilated Cardiomyopathy market report provides current treatment practices, emerging drugs, Dilated Cardiomyopathy market share of the individual therapies, current and forecasted Dilated Cardiomyopathy market size from 2017 to 2030 segmented by seven major markets.

Key Points: 
  • The Dilated Cardiomyopathy market report provides current treatment practices, emerging drugs, Dilated Cardiomyopathy market share of the individual therapies, current and forecasted Dilated Cardiomyopathy market size from 2017 to 2030 segmented by seven major markets.
  • The Dilated Cardiomyopathy epidemiology division provides the insights about historical and current Dilated Cardiomyopathy patient pool and forecasted trend for each seven major countries.
  • Drug chapter segment of the Dilated Cardiomyopathy report encloses the detailed analysis of Dilated Cardiomyopathy marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.
  • The publisher performs Competitive and Market Intelligence analysis of the Dilated Cardiomyopathy Market by using various Competitive Intelligence tools that includes - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc.

Worldwide Dilated Cardiomyopathy (DCM) Market Insights, Epidemiology and Forecast - 2030 - ResearchAndMarkets.com

Thursday, August 20, 2020 - 12:57pm

The "Dilated Cardiomyopathy (DCM) - Market Insights, Epidemiology and Market Forecast - 2030" drug pipelines report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Dilated Cardiomyopathy (DCM) - Market Insights, Epidemiology and Market Forecast - 2030" drug pipelines report has been added to ResearchAndMarkets.com's offering.
  • The Dilated Cardiomyopathy market report provides current treatment practices, emerging drugs, Dilated Cardiomyopathy market share of the individual therapies, current and forecasted Dilated Cardiomyopathy market size from 2017 to 2030 segmented by seven major markets.
  • The Dilated Cardiomyopathy epidemiology division provides the insights about historical and current Dilated Cardiomyopathy patient pool and forecasted trend for each seven major countries.
  • The disease epidemiology covered in the report provides historical as well as forecasted Dilated Cardiomyopathy epidemiology segmented as [Total Prevalent Population of Dilated Cardiomyopathy, Total Diagnosed Population of Dilated Cardiomyopathy, Familial and non-familial cases of Dilated Cardiomyopathy, Gender-Specific Cases of Dilated Cardiomyopathy, and Total Treated Cases of Dilated Cardiomyopathy] scenario of Dilated Cardiomyopathy in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2017 to 2030.

2020 Dilated Cardiomyopathy Pipeline Research Monitor - ResearchAndMarkets.com

Monday, July 27, 2020 - 9:57am

The "Dilated Cardiomyopathy Pipeline Research Monitor, 2020 - Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status and Outlook" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Dilated Cardiomyopathy Pipeline Research Monitor, 2020 - Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status and Outlook" report has been added to ResearchAndMarkets.com's offering.
  • The Dilated Cardiomyopathy pipeline Research Monitor, 2020 report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.
  • This Dilated Cardiomyopathy pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.
  • The competitive intelligence report on Dilated Cardiomyopathy presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Dilated Cardiomyopathy pipeline.

MyoKardia Announces Positive Data from Phase 2a Clinical Trial of Danicamtiv Presented at ESC’s HFA Discoveries with Simultaneous Publication in European Journal of Heart Failure

Monday, June 22, 2020 - 1:00pm

Results from both the clinical and nonclinical studies of danicamtiv were featured at the European Society of Cardiologys Heart Failure Association (HFA) Discoveries online event and published simultaneously in the European Journal of Heart Failure .

Key Points: 
  • Results from both the clinical and nonclinical studies of danicamtiv were featured at the European Society of Cardiologys Heart Failure Association (HFA) Discoveries online event and published simultaneously in the European Journal of Heart Failure .
  • The primary endpoint for the Phase 2a study was to assess the clinical safety and tolerability of danicamtiv in patients with chronic HFrEF.
  • The nonclinical and Phase 2a clinical data were simultaneously published in an article titled, Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a Phase 2a trial .
  • MyoKardia intends to advance danicamtiv in further clinical studies to characterize clinical benefit, starting with a Phase 2 clinical trial in patients with genetic dilated cardiomyopathy.

Dilated Cardiomyopathy - Pipeline Review, H1 2020 | Key Players Include Berlin Cures Holding AG, Celixir, Heartseed Among Others - ResearchAndMarkets.com

Friday, February 14, 2020 - 1:15pm

The Dilated Cardiomyopathy (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Dilated Cardiomyopathy and features dormant and discontinued projects.

Key Points: 
  • The Dilated Cardiomyopathy (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Dilated Cardiomyopathy and features dormant and discontinued projects.
  • The pipeline guide reviews pipeline therapeutics for Dilated Cardiomyopathy (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide reviews key companies involved in Dilated Cardiomyopathy (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • Formulate corrective measures for pipeline projects by understanding Dilated Cardiomyopathy (Cardiovascular) pipeline depth and focus of Indication therapeutics.

MyoKardia Announces Positive MYK-491 Data; Advancing Program into Targeted Genetic Dilated Cardiomyopathy Population

Monday, October 28, 2019 - 12:30pm

The data obtained in this Phase 2a trial have satisfied our pre-specified criteria for advancing MYK-491 into later stages of development.

Key Points: 
  • The data obtained in this Phase 2a trial have satisfied our pre-specified criteria for advancing MYK-491 into later stages of development.
  • Data from our planned Phase 2 study in genetic DCM will inform further segmentation of the broader systolic heart failure patient population and enable efficient late-stage development efforts.
  • Dilated cardiomyopathy, regardless of cause, is the most common diagnosis in patients requiring either mechanical circulatory support or a cardiac transplant.
  • Similarly to other DCM patients, genetic DCM patients develop enlargement of the heart, fluid accumulation and shortness of breath.